CA2363503A1 - Diagnostics and therapeutics for drusen associated ocular disorders - Google Patents

Diagnostics and therapeutics for drusen associated ocular disorders Download PDF

Info

Publication number
CA2363503A1
CA2363503A1 CA002363503A CA2363503A CA2363503A1 CA 2363503 A1 CA2363503 A1 CA 2363503A1 CA 002363503 A CA002363503 A CA 002363503A CA 2363503 A CA2363503 A CA 2363503A CA 2363503 A1 CA2363503 A1 CA 2363503A1
Authority
CA
Canada
Prior art keywords
therapeutics
diagnostics
ocular disorders
associated ocular
drusen associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002363503A
Other languages
French (fr)
Other versions
CA2363503C (en
Inventor
Gregory S. Hageman
Robert F. Mullins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation UIRF
Original Assignee
University Of Iowa Research Foundation
Gregory S. Hageman
Robert F. Mullins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Iowa Research Foundation, Gregory S. Hageman, Robert F. Mullins filed Critical University Of Iowa Research Foundation
Publication of CA2363503A1 publication Critical patent/CA2363503A1/en
Application granted granted Critical
Publication of CA2363503C publication Critical patent/CA2363503C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Abstract

The invention relates to methods for treating, preventing and diagnosing drusen-associated disorders.
CA002363503A 1999-03-05 2000-03-06 Diagnostics and therapeutics for drusen associated ocular disorders Expired - Fee Related CA2363503C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12305299P 1999-03-05 1999-03-05
US60/123,052 1999-03-05
US51023000A 2000-02-22 2000-02-22
US09/510,230 2000-02-22
PCT/US2000/005858 WO2000052479A2 (en) 1999-03-05 2000-03-06 Diagnostics and therapeutics for drusen associated ocular disorders

Publications (2)

Publication Number Publication Date
CA2363503A1 true CA2363503A1 (en) 2000-09-08
CA2363503C CA2363503C (en) 2009-03-10

Family

ID=26821176

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002363503A Expired - Fee Related CA2363503C (en) 1999-03-05 2000-03-06 Diagnostics and therapeutics for drusen associated ocular disorders

Country Status (4)

Country Link
EP (1) EP1161686A2 (en)
AU (1) AU3395800A (en)
CA (1) CA2363503C (en)
WO (1) WO2000052479A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114592B2 (en) 2008-03-18 2012-02-14 Cambridge Enterprise Limited Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275782A1 (en) 1999-04-20 2006-12-07 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
ES2316446T3 (en) 2000-04-29 2009-04-16 University Of Iowa Research Foundation DIAGNOSIS AND THERAPEUTICS FOR DISORDERS RELATED TO MACULAR DEGENERATION.
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
US6986995B2 (en) * 2002-02-28 2006-01-17 Prometheus Laboratories, Inc. Methods of diagnosing liver fibrosis
US8088579B2 (en) * 2005-02-14 2012-01-03 University Of Iowa Research Foundation Complement factor H for diagnosis of age-related macular degeneration
US8088773B2 (en) * 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
US20080318264A1 (en) * 2005-09-09 2008-12-25 University Of Iowa Research Foundation Biomarkers Associated With Age-Related Macular Degeneration
AU2013274582A1 (en) 2012-06-11 2015-01-22 Macuclear, Inc. Therapeutic formulation and methods of treatment
GB201306627D0 (en) 2013-04-11 2013-05-29 Thompson Richard Marker
AU2014236782B2 (en) 2013-03-14 2019-01-03 Baxalta GmbH Factor H for treatment of rheumatoid arthritis
DK2968457T3 (en) 2013-03-14 2018-10-29 Baxalta Inc FACTOR H FOR TRANSPLANTATION
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
US9423394B2 (en) * 2013-12-13 2016-08-23 TheraOptix, Inc. Retinal pigment epithelial primary cell culture system producing subcellular deposits
WO2018039030A1 (en) 2016-08-23 2018-03-01 University Of Maryland, Baltimore Methods for detecting and/or predicting age-related macular degeneration and/or alzheimer's disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114592B2 (en) 2008-03-18 2012-02-14 Cambridge Enterprise Limited Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof

Also Published As

Publication number Publication date
EP1161686A2 (en) 2001-12-12
WO2000052479A3 (en) 2001-02-01
AU3395800A (en) 2000-09-21
CA2363503C (en) 2009-03-10
WO2000052479A2 (en) 2000-09-08

Similar Documents

Publication Publication Date Title
CA2407715A1 (en) Diagnostics and therapeutics for macular degeneration-related disorders
CA2363503A1 (en) Diagnostics and therapeutics for drusen associated ocular disorders
AU2002366641A1 (en) Methods for inhibiting ocular processes
HK1040266A1 (en) Titanium alloy and method for producing the same.
ZA200108530B (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents.
CA2332521A1 (en) Pharmaceutical composition for treating or preventing sleep disorders
ZA993364B (en) Novel 4-phenylpiperidines for the treatment of pruritic dermatoses.
WO2001016377A3 (en) Diagnostics and therapeutics for osteoporosis
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
AU3824599A (en) Method for producing (s,s)-benzyl-2,8-diazabicyclo{4.3.0}nonane
CA2347863A1 (en) Treatment of disorders of the outer retina
ZA993852B (en) Diaza-Spiro (3,5)nonane derivates.
CA2384433A1 (en) Novel betulinic acid derivatives having antiangiogenic activity, processes for producing such derivatives and their use for treating tumor associated angiogenesis
ZA997027B (en) High-temperature, water-based lubricant and process for making the same.
ZA200002941B (en) Process for the preparation of butanediol, butyrolactone and tetrahydrofuran.
WO2002030354A3 (en) Uridine therapy for patients with elevated purine levels
CY2362B1 (en) Use of 1-hydroxy-2-pyridone for the treatment of seborrheic dermatitis.
CA2369825A1 (en) Microstructured components
WO1999051779A3 (en) Glaucoma therapeutics and diagnostics
HK1038510A1 (en) Use of neurotrophic factor stimulators for the treamtent of ophthalmic neurodegenerative diseases.
ZA966749B (en) Endoparasiticidal compositions based on didepsipeptides, new didepsipeptides and processes for their preparation.
MX9603516A (en) Oxime derivatives and their use as pesticides.
ZA200002546B (en) Sorbate-preserved compositions, method for the manufacture thereof and their use.
ZA200102818B (en) Process for the preparation of 4,4'-dihalogen-O-hydroxydiphenyl compounds.
ZA991215B (en) Process for the preparation of 1,3-disubstituted 2-nitroguanidines.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180306